Close menu




PANGENOMIC HEALTH INC

Photo credits: pixabay.com

Commented by Fabian Lorenz on June 3rd, 2025 | 07:10 CEST

SHOCK for RENK, "BUY" rating for Novo Nordisk, and PanGenomic Health follows in the footsteps of Hims & Hers

  • Digitization
  • Technology
  • Healthcare
  • Biotechnology

Shock for RENK & Co.! Yesterday afternoon, news broke that the EU plans to tap into the billions in profits made by defense companies. After all, these companies are facing a golden age. The shares ended their record run yesterday. The alternative medicine and dietary supplements sector is currently experiencing a boom in the US. PanGenomic Health wants a piece of that multi-billion-dollar market. The newcomer is launching an AI-based app offering recommendations, a marketplace, and diagnostics. The rollout will begin this summer. Anyone who missed out on the 800% gains at Hims & Hers should take a look at this newcomer. Novo Nordisk is a core investment in the pharmaceutical sector. However, expectations for the blockbuster drug Ozempic were likely set too high. After the stock's crash, things are now looking better again.

Read